OMERACT 1 - 5
OMERACT 1
Volume 20, No. 3
OMERACT Conference on Outcome Measures in RA Clinical Trials: Introduction
P. Tugwell, M. Boers .........528
PDF
OMERACT Conference on Outcome Measures in RA Clinical Trials: Conclusion
P. Tugwell, M. Boers .........590
PDF
Volume 21, Supplement 41
World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in RA Clinical Trials
M. Boers, P. Tugwell, D.T. Felson, et al .........86
PDF
OMERACT 2
Volume 22, No. 5-7
OMERACT: State of the "ACT"
M. Boers, P.M. Brooks, P. Tugwell .........980
PDF
Toxicity of Antirheumatic Drugs
P.M. Brooks and R.O. Day for the Toxicity Workgroup Leaders .........998
PDF
Health Status Instruments/Utilities
N. Bellamy, M. Boers, D. Felson, et al .........1203
PDF
Economic Analysis Alongside Clinical Trials: Practical Considerations
M. Drummond, B. O'Brien for the Economics Workgroup .........1418
PDF
OMERACT II Conference -- Outcome Measures in RA Clinical Trials: Conclusion
P. Tugwell, M. Boers, P. Brooks .........1431
PDF
OMERACT 3
Volume 24, No. 4-6
OMERACT III The "ACT" Revisited
P. Brooks, M. Boers, P. Tugwell .........764
PDF
Recommendations for a Core Set of Outcome Measures for Future Phase III Clinical Trials in Knee, Hip, and Hand OA. Consensus Development at OMERACT III
N. Bellamy, J. Kirwan, M. Boers, et al .........799
PDF
Psychosocial Measures in Musculoskeletal Trials
S.P. Newman .........979
PDF
Psychosocial Measures
P. Brooks, A.C. McFarlane, S. Newman, J.J. Rasker .........1008
PDF
Guidelines of Osteoporosis Trials
P.N. Sambrook, S.R. Cummings, J.A. Eisman, et al .........1234
PDF
OMERACT 4
Volume 25, No. 2
The OMERACT Filter for Outcome Measures in Rheumatology
M. Boers, P. Brooks, C.V. Strand, P. Tugwell .........198
PDF
Volume 26, No. 1-4
OMERACT IV: Fourth International Consensus Conference on Outcome Measures in Rheumatology: Introduction
M. Boers, P. Brooks, V. Strand, P. Tugwell .........199
PDF
Reporting Requirements for Longitudinal Observational Studies in Rheumatology
A. Silman, D. Symmons .........481
PDF
Preliminary Core Set of Domains and Reporting Requirements for Longitudinal Observational Studies in Rheumatology
F. Wolfe, M. Lassere, D.M.F.M. van der Heijde, et al .........484
PDF
Outcome Measures To Be Used in Clinical Trials in SLE
V. Strand, D.D. Gladman, D. Isenberg, M. Petri, J. Smolen, P. Tugwell .........490
PDF
Randomized Clinical Trials and Longitudinal Observational Studies in SLE: Consensus on a Preliminary Core Set of Outcome Domains
J.S. Smolen, V. Strand, M. Cardiel, et al .........504
PDF
ACR and EULAR Improvement Criteria Have Comparable Validity in RA Trials
A.M. Van Gestel, J.J. Anderson, P.L.C.M. van Riel, et al .........705
PDF
Smallest Detectable Difference in Radiological Progression
M. Lassere, M. Boers, D. van der Heijde, et al .........731
PDF
Imaging in RA: Results of Group Discussions
E.T.H. Molenaar, M. Boers, D.M.F.M. van der Heijde, et al .........749
PDF
Which Domains Should Be Included in a Core Set for Endpoints in Ankylosing Spondylitis? Introduction to the AS Module of OMERACT IV D.M.F.M. van der Heijde, S.M. van der Linden, N. Bellamy, et al .........945
PDF
AS: Plenary Discussion and Results of Voting on Selection of Domains and Some Specific Instruments
D.M.F.M. van der Heijde, S.M. van der Linden, M. Dougados, et al .........1003
PDF
OMERACT 5
Volume 28, No. 2-5
OMERACT 5: International Consensus Conference on Outcome Measures in Rheumatology: Introduction
P. Tugwell, M. Boers, P.M. Brooks, L. Simon, C.V. Strand .........395
PDF
Minimal Clinically Important Difference Module: Introduction
G.A. Wells .........398
PDF
Looking for Important Change/Differences in Studies of Responsiveness
D.E. Beaton, C. Bombardier, J.N. Katz, et al .........400
PDF
Minimal Clinically Important Difference Module: Summary, Recommendations, and Research Agenda
G.A. Wells, J. Anderson, D. Beaton, et al .........452
PDF
OMERACT 5 Economics Working Group Report: Introduction
S.E. Gabriel .........640
PDF
OMERACT 5 Economics Working Group: Summary, Recommendations, and Research Agenda
S. Gabriel, M. Drummond, D. Coyle, et al .........670
PDF
OMERACT 5 Imaging Working Group Report on Plain Films: Introduction
D.M.F.M. van der Heijde .........880
PDF
Minimal Clinically Important Difference in Plain Films in RA: Group Discussions, Conclusions, and Recommendations
D.M.F.M. van der Heijde, M. Lassere, J.P. Edmonds, et al .........914
PDF
OMERACT 5 MRI Module: Introduction
J. Edmonds .........1133
PDF
MRI in RA: Summary of OMERACT Activities, Current Status, and Plans
P. Conaghan, J.P. Edmonds, P. Emery, et al .........1158
PDF
OMERACT 5 Drug Safety Working Group Report: Introduction
P.M. Brooks, R.O. Day .........1162
PDF
Standardizing Assessment of Adverse Effects in Rheumatology Clinical Trials. Status of OMERACT Toxicity Working Group March 2000: Towards a Common Understanding of Comparative Toxicity/Safety Profiles for Antirheumatic Therapies
T.G. Woodworth, D.E. Furst, V. Strand, et al .........1163
PDF
Drug Safety Module: Summary and Recommendations
P.M. Brooks, R.O. Day .........1192
PDF